乐观
$133.17
情景价格
$27.920
+0.335 (+1.20%)收盘时
Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products.
Hims & Hers Health Inc is currently not a strong buy due to its recent performance and financial instability. The current price is $27.71, with a significant decline of 42.55% over the past year. Additionally, the RSI is at 36.78, indicating that the stock is nearing oversold territory but has not yet reversed its trend. The forward P/E ratio is high at 73.53, suggesting that the stock may be overvalued given its current earnings situation. The main risk is the ongoing class action lawsuit related to FTC allegations, which could further impact investor sentiment and stock performance.
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Hims & Hers Health Inc. Class Action Notice Issued

Hims & Hers Faces Securities Class Action Lawsuit

Hims & Hers Health Inc. Class Action Lawsuit Notification

Hims & Hers Health Faces Class Action Lawsuit Over FTC Allegations

Hims & Hers Faces Securities Class Action Amid FTC Allegations
Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. It operates in the Healthcare sector (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE industry).
Hims & Hers Health Inc is currently not a strong buy due to its recent performance and financial instability. The current price is $27.71, with a significant decline of 42.55% over the past year. Additionally, the RSI is at 36.78, indicating that the stock is nearing oversold territory but has not yet reversed its trend. The forward P/E ratio is high at 73.53, suggesting that the stock may be overvalued given its current earnings situation. The main risk is the ongoing class action lawsuit related to FTC allegations, which could further impact investor sentiment and stock performance.

Someone once told me about the 20SMA/50EMA crossover, so I'm always watching for it. $HIMS is tight around this crossover and looks set for a big expansion from here.
展开
HIMS stock ended a three-day decline on peptide hopes: the Trump administration is reviewing a plan that could open a $2.2B market. $HIMS
展开
$HIMS The price is wasting time ... but it's running out of room. Imminent resolution. Weekly chart
展开

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。